title: [Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children].
abstract: OBJECTIVE
  To compare the efficacy of valproic acid (VPA) and lamotrigine as a monotherapy for absence epilepsy in children.
  
  
  METHODS
  A randomized, open-label design was used. Childhood absence epilepsy was diagnosed based on the presence of typical seizures and video-EEG findings. Eligible patients were randomly treated with VPA or lamotrigine. All patients were followed up for 12 months.
  
  
  RESULTS
  Forty-five out of 48 eligible children completed the study. There were 23 children in the VPA group and 22 children in the lamotrigine group. Seventeen children were seizure-free in the VPA group 12 months after treatment. Fifteen out of the 17 children showed normal EEG (no epileptic-formed discharge). Twelve children were seizure-free in the lamotrigine group 12 months after treatment. The proportion showing normal EEG in the lamotrigine group (6/22, 27.3%) was significantly lower than that in the VPA group (15/23, 65.2%) (P<0.05). Severe adverse effects were not found in both groups.
  
  
  CONCLUSIONS
  Both VPA and lamotrigine are safe and efficacious for treatment of absence seizures in children. VPA appears to be better than lamotrigine in tapering epileptic-formed discharge.
authors.affiliation: Shenzhen Children's Hospital, Shenzhen, Guangdong, China. hts249@163.com
authors.forename: Tie-Shuan
authors.initials: TS
authors.lastname: Huang
authors.forename: Jin-Lan
authors.initials: JL
authors.lastname: Zhu
authors.forename: Bing
authors.initials: B
authors.lastname: Li
authors.forename: Yan
authors.initials: Y
authors.lastname: Hu
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.forename: Jian-Xiang
authors.initials: JX
authors.lastname: Liao
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography; D004832:Epilepsy, Absence / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D014635:Valproic Acid; D000077213:Lamotrigine